TY - JOUR
T1 - Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure
AU - Matsuzaki, Masunori
AU - Yamamoto, Kazuhiro
AU - Yano, Masafumi
AU - Nakamura, Koki
AU - Miyata, Yuko
AU - Sugiura, Kenkichi
AU - Nakata, Emi
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
This study was sponsored and supported by Takeda Pharmaceutical Company Limited (Osaka, Japan) with regard to design, implementation, monitoring, analysis, and other activities related to this study. We acknowledge the investigators and other staff members who participated in this study. The study centers were as follows: Shiroishi Kojinkai Hospital, Asahikawa Rehabilitation Hospital, Kihara Cardiovascular Clinic, Morino Izumi Clinic, Dobashi Clinic, Sendai Medical Center, Fukushima Daiichi Hospital, Moriya Keiyu Hospital, Mito General Hospital, Mito Medical Center, Kobari General Hospital, Ayase Heart Hospital, Ooimachi Medical Clinic, Tokyo Heart Center, Kitasato Institute Hospital, JR Tokyo General Hospital, Tachibanadai Hospital, Kanagawa Cardiovascular and Respiratory Center, Yokohama Medical Center, Gifu Central Hospital, Gifu Prefectural General Medical Center, Shizuoka Medical Center, Nagoya Ekisaikai Hospital, Chubu Rosai Hospital, Daiyukai General Hospital, Hirata Cardiovascular Hospital, Horikawa Hospital, Ijinkai Takeda General Hospital, Koseikai Takeda Hospital, Higashiyama Takeda Hospital, Tatsumi Clinic, Hikosaka Clinic, Kitano Hospital, Takatsuki Red Cross Hospital, Hyogo Brain and Heart Center, Kobe Medical Center, Yamashita Shinryojo Medical Center, KKR Takamatsu Hospital, Social Insurance Ritsurin Hospital, Kure Medical Center and Chugoku Cancer Center, Mazda Hospital, Fukuoka Wajiro Hospital, Saiseikai Fukuoka General Hospital, Shin Yukuhashi Hospital, Shin-Koga Hospital, Nakamura Cardiovascular Clinic, Nagasaki Medical Center, Oita Oka Hospital, and Hashino Clinic.
PY - 2013/4
Y1 - 2013/4
N2 - Background: Chronic heart failure (CHF) is an increasingly common cardiovascular disease despite recent advances in its diagnosis and management. Methods and results: A multicenter, open-label study was designed to assess the efficacy and safety of 60-week treatment with candesartan in Japanese patients with mild to moderate CHF. Primary efficacy endpoints were changes from baseline in plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), end-diastolic dimension, and New York Heart Association (NYHA) functional class. Two hundred and eighty-nine eligible patients were divided into 2 groups based on the daily dose at the end of treatment: high-dose (HD, 8. mg, N=. 170) and low-dose (LD, 2 or 4. mg, N=. 119). Neither plasma BNP levels nor LVEF changed from the baseline to the end of treatment in the LD group, whereas BNP significantly improved from 61.6 to 50.1. pg/mL (. p=. 0.0005) and LVEF from 57.2 to 60.1% (. p=. 0.0005) in the HD group. The changes in NYHA functional class were comparable between groups: 21.2% improved and 76.3% unchanged in the LD group and 20.6% improved and 79.4% unchanged in the HD group. No safety concerns were observed in either group. Conclusions: HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients. Both LD and HD candesartan were well tolerated in CHF patients.
AB - Background: Chronic heart failure (CHF) is an increasingly common cardiovascular disease despite recent advances in its diagnosis and management. Methods and results: A multicenter, open-label study was designed to assess the efficacy and safety of 60-week treatment with candesartan in Japanese patients with mild to moderate CHF. Primary efficacy endpoints were changes from baseline in plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), end-diastolic dimension, and New York Heart Association (NYHA) functional class. Two hundred and eighty-nine eligible patients were divided into 2 groups based on the daily dose at the end of treatment: high-dose (HD, 8. mg, N=. 170) and low-dose (LD, 2 or 4. mg, N=. 119). Neither plasma BNP levels nor LVEF changed from the baseline to the end of treatment in the LD group, whereas BNP significantly improved from 61.6 to 50.1. pg/mL (. p=. 0.0005) and LVEF from 57.2 to 60.1% (. p=. 0.0005) in the HD group. The changes in NYHA functional class were comparable between groups: 21.2% improved and 76.3% unchanged in the LD group and 20.6% improved and 79.4% unchanged in the HD group. No safety concerns were observed in either group. Conclusions: HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients. Both LD and HD candesartan were well tolerated in CHF patients.
UR - http://www.scopus.com/inward/record.url?scp=84875674589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875674589&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2012.12.004
DO - 10.1016/j.jjcc.2012.12.004
M3 - Article
C2 - 23419641
AN - SCOPUS:84875674589
SN - 0914-5087
VL - 61
SP - 267
EP - 274
JO - Journal of Cardiology
JF - Journal of Cardiology
IS - 4
ER -
